It is the world’s largest advanced therapies partnering event that incorporates the entire ecosystem of this specialty. This year the event has attracted 2,000 attendees, 150 exhibitors and 300 speakers representing every major stakeholder group.

The Business Development Director of VIVEbiotech, Dr. Natalia Elizalde, is attending the event where she is holding numerous bilateral meetings with clients in execution, potential clients and/or collaborators in the field of gene therapy and cellular cancer immunotherapy, all of which contemplating the use of lentiviral vectors to achieve their projects.

VIVEbiotech, a biotechnology-based company specializing in the development and manufacture of lentiviral vectors, thus opens the cycle of attendance at events that has planned to attend this year.